Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 12/20 | 0.58 |
| ▸ | NOS3 | P29474 | 11/20 | 0.58 |
| ▸ | NOS1 | P29475 | 11/20 | 0.58 |
| ▸ | GRIN2B | Q13224 | 5/20 | 0.52 |
| ▸ | GRIN1 | Q05586 | 4/20 | 0.52 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.48 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.47 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.47 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.47 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.47 |
| ▸ | GRIN3A | Q8TCU5 | 2/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4646866 | 1.00 | NOS2 (0.58) | NOS2NOS3NOS1GRIN2BGRIN1 | |
| Bromide SCHEMBL11806754 | 0.98 | NOS2 (0.59) | NOS2NOS3NOS1GRIN2BGRIN1 | |
| SCHEMBL8772898 | 0.81 | NOS2 (0.60) | NOS2GRIN2BGRIN1HRH4HRH3 | |
| Iodide SCHEMBL10591785 | 0.79 | NOS2 (0.58) | NOS2NOS3NOS1GRIN2BGRIN1 | |
| SCHEMBL13533929 | 0.77 | GRIN2B (0.50) | NOS2NOS3NOS1GRIN2BGRIN1 | |
| SCHEMBL20675953 | 0.74 | NOS2 (0.96) | NOS2NOS3NOS1GRIN2BGRIN1 | |
| SCHEMBL14291059 | 0.74 | NOS2 (0.96) | NOS2NOS3NOS1GRIN2BGRIN1 | |
| Hydrochloric Acid SCHEMBL27493867 | 0.74 | NOS2 (0.43) | NOS2NOS3NOS1GRIN2BGRIN1 | |
| SCHEMBL45769 | 0.73 | GRIN2B (0.68) | NOS2GRIN2BGRIN1HRH4GRIN2D | |
| SCHEMBL1387776 | 0.73 | NOS1 (1.00) | NOS2NOS3NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150210680-A1 | AMINODIHYDROTHIAZINE DERIVATIVES | SHIONOGI & CO (JP) | 2015-07-30 | — | — | US | disclosed |
| US-8895548-B2 | Pharmaceutical composition for treating alzheimer's disease | SHIONOGI & CO., LTD. (JP) | 2014-11-25 | — | — | US | disclosed |
| US-8815851-B2 | Aminodihydrothiazine derivatives | SHIONOGI & CO., LTD. (JP) | 2014-08-26 | — | — | US | disclosed |
| US-20140058097-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING ALZHEIMER'S DISEASE | SHIONOGI & CO., LTD. (JP) | 2014-02-27 | — | — | US | disclosed |
| US-20130158260-A1 | AMINODIHYDROTHIAZINE DERIVATIVES | SHIONOGI & CO., LTD. (JP) | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158260-A1 | AMINODIHYDROTHIAZINE DERIVATIVES | BACE1, BACE2, APP | NOS2 1938/4885NOS3 1553/4885NOS1 579/4885 |
| US-20140058097-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING ALZHEIMER'S DISEASE | NR1H2, NR1H3, NR0B1 | NOS2 1899/4885NOS3 1833/4885NOS1 1701/4885 |
| US-20150210680-A1 | AMINODIHYDROTHIAZINE DERIVATIVES | BACE1, BACE2, APP | NOS2 2252/4885NOS3 2053/4885NOS1 992/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.